These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26489829)

  • 1. Predictive In Vivo Models for Oncology.
    Behrens D; Rolff J; Hoffmann J
    Handb Exp Pharmacol; 2016; 232():203-21. PubMed ID: 26489829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery.
    Ruggeri BA; Camp F; Miknyoczki S
    Biochem Pharmacol; 2014 Jan; 87(1):150-61. PubMed ID: 23817077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically engineered models have advantages over xenografts for preclinical studies.
    Becher OJ; Holland EC
    Cancer Res; 2006 Apr; 66(7):3355-8, discussion 3358-9. PubMed ID: 16585152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of genetically engineered mouse models of colorectal carcinoma to enable translational biology and drug development.
    Roper J; Martin ES; Hung KE
    Curr Protoc Pharmacol; 2014 Jun; 65():14.29.1-10. PubMed ID: 24934606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug screening in 3D in vitro tumor models: overcoming current pitfalls of efficacy read-outs.
    Santo VE; Rebelo SP; Estrada MF; Alves PM; Boghaert E; Brito C
    Biotechnol J; 2017 Jan; 12(1):. PubMed ID: 27966285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translational In Vivo Models for Cardiovascular Diseases.
    Fliegner D; Gerdes C; Meding J; Stasch JP
    Handb Exp Pharmacol; 2016; 232():223-34. PubMed ID: 26552402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical in vitro models from genetically engineered mice for breast and colon cancer (Review).
    Telang N; Katdare M
    Oncol Rep; 2011 May; 25(5):1195-201. PubMed ID: 21399881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology.
    Saito R; Kobayashi T; Kashima S; Matsumoto K; Ogawa O
    Int J Clin Oncol; 2020 May; 25(5):831-841. PubMed ID: 31407168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model.
    Kunz-Schughart LA; Freyer JP; Hofstaedter F; Ebner R
    J Biomol Screen; 2004 Jun; 9(4):273-85. PubMed ID: 15191644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translational value of mouse models in oncology drug development.
    Gould SE; Junttila MR; de Sauvage FJ
    Nat Med; 2015 May; 21(5):431-9. PubMed ID: 25951530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiologically relevant in vitro tumor models for drug screening.
    Das V; Bruzzese F; Konečný P; Iannelli F; Budillon A; Hajdúch M
    Drug Discov Today; 2015 Jul; 20(7):848-55. PubMed ID: 25908576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetically modified mouse models for biomarker discovery and preclinical drug testing.
    Kucherlapati R
    Clin Cancer Res; 2012 Feb; 18(3):625-30. PubMed ID: 22298895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Models of metastasis in drug discovery.
    Talmadge JE
    Methods Mol Biol; 2010; 602():215-33. PubMed ID: 20012401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mouse tumour models to guide drug development and identify resistance mechanisms.
    Das Thakur M; Pryer NK; Singh M
    J Pathol; 2014 Jan; 232(2):103-11. PubMed ID: 24122209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical, Pathological, and Ethical Considerations for the Conduct of Clinical Trials in Dogs with Naturally Occurring Cancer: A Comparative Approach to Accelerate Translational Drug Development.
    Regan D; Garcia K; Thamm D
    ILAR J; 2018 Dec; 59(1):99-110. PubMed ID: 30668709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stem cell models for drug discovery and toxicology studies.
    Liu W; Deng Y; Liu Y; Gong W; Deng W
    J Biochem Mol Toxicol; 2013 Jan; 27(1):17-27. PubMed ID: 23293059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fit-for purpose use of mouse models to improve predictivity of cancer therapeutics evaluation.
    Wartha K; Herting F; Hasmann M
    Pharmacol Ther; 2014 Jun; 142(3):351-61. PubMed ID: 24412280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementation and Use of State-of-the-Art, Cell-Based In Vitro Assays.
    Langer G
    Handb Exp Pharmacol; 2016; 232():171-90. PubMed ID: 26424721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling.
    Sandercock AM; Rust S; Guillard S; Sachsenmeier KF; Holoweckyj N; Hay C; Flynn M; Huang Q; Yan K; Herpers B; Price LS; Soden J; Freeth J; Jermutus L; Hollingsworth R; Minter R
    Mol Cancer; 2015 Jul; 14():147. PubMed ID: 26227951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Preclinical models in oncology].
    Vrignaud P
    Bull Cancer; 2011 Nov; 98(11):1355-61. PubMed ID: 22023796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.